Information Statement from the NHS England Clinical Panel for Nusinersen

11 June 2020

This is about access to the risdiplam Compassionate Use Programme for anyone who has SMA Type 1 or 2 who is already receiving nusinersen but who has had their treatment interrupted because of COVID-19. 

Read the statement